|
Variables
|
Before PSM
|
After PSM
|
|---|
|
n
|
Non-RT (%)
|
RT (%)
|
P
|
n
|
Non-RT (%)
|
RT (%)
|
P
|
|---|
|
Age (years)
|
|
65–69
|
681
|
123 (10.0)
|
558 (25.5)
|
< 0.001
|
244
|
122 (12.1)
|
122 (12.1)
|
1
|
|
70–74
|
840
|
210 (17.1)
|
630 (28.8)
| |
420
|
210 (20.8)
|
210 (20.8)
| |
|
75–79
|
803
|
251 (20.5)
|
552 (25.2)
| |
490
|
245 (24.3)
|
245 (24.3)
| |
|
> 79
|
1092
|
641 (52.3)
|
451 (20.6)
| |
866
|
433 (42.9)
|
433 (42.9)
| |
|
Race/ethnicity
|
|
Non-Hispanic White
|
2829
|
1035 (84.5)
|
1794 (81.9)
|
0.039
|
1694
|
847 (83.9)
|
847 (83.9)
|
1
|
|
Non-Hispanic Black
|
214
|
76 (6.2)
|
138 (6.3)
| |
116
|
58 (5.7)
|
58 (5.7)
| |
|
Hispanic (All Races)
|
199
|
69 (5.6)
|
130 (5.9)
| |
122
|
61 (6.0)
|
61 (6.0)
| |
|
Other
|
174
|
45 (3.7)
|
128 (5.9)
| |
88
|
44 (4.4)
|
44 (4.4)
| |
|
Grade
|
|
Well-differentiated
|
2279
|
837 (68.3)
|
1442 (65.8)
|
0.314
|
1358
|
679 (67.2)
|
679 (67.2)
|
1
|
|
Moderately differentiated
|
1047
|
356 (29.1)
|
691 (31.5)
| |
622
|
311 (30.8)
|
311 (30.8)
| |
|
Poorly differentiated/undifferentiated
|
90
|
32 (2.6)
|
58 (2.6)
| |
40
|
20 (2.0)
|
20 (2.0)
| |
|
Tumor stage
|
|
T1
|
2848
|
1000 (81.6)
|
1848 (84.3)
|
0.041
|
1672
|
836 (82.8)
|
836 (82.8)
|
1
|
|
T2
|
568
|
225 (18.4)
|
343 (15.7)
| |
348
|
174 (17.2)
|
174 (17.2)
| |
|
Chemotherapy
|
|
No/unknown
|
3343
|
1213 (99.0)
|
2130 (97.2)
|
< 0.001
|
2000
|
1000 (99.0)
|
1000 (99.0)
|
1
|
|
Yes
|
73
|
12 (1.0)
|
61 (2.8)
| |
20
|
10 (1.0)
|
10 (1.0)
| |
- PSM propensity score matching; RT radiotherapy
